This study aimed to explore the effects of raloxifene (Rx) and estradiol (E2) on prothrombin time (PT), partial thromboplastin time (APTT), coagulation factors (VII, X, XI), and fibrinogen concen-trations in rats. Rats were ovariectomized 11 days prior to starting the treatment. Then they re-ceived Rx or E2 (1 to 1000 µg/Kg) or propylene glycol (0.3 ml; vehicle, V) subcutaneously for three consecutive days. Plasmas were collected to measure the hemostatic parameters. Rx significantly increased PT (8%, at 1000 µg/Kg; p<0.05) and APTT at all doses evaluated (32, 70, 67, 30%; p<0.05, respectively). Rx (1 to 1000 µg/Kg) decreased the activity of factor VII by -20, -40, -37, and -17% (p<0.05), respectively, while E2 increased it by 9, 34, 52, and 29%; Rx reduced factor X activity at 10 and 100 µg/kg doses (-30, and -30% p<0.05), while E2 showed an increment of 24% with 1000 µg/kg dose only; Rx (1-100 µg/Kg) diminished FXI activity (-71, -62, -66; p<0.05), while E2 (1 and 10 µg/Kg) diminished it in -60 and -38, respectively (p<0.05); Rx (1000 µg/Kg) produced an increment of 29% (p<0.05) in fibrinogen concentration, but not E2. Our findings suggest that raloxifene has a pro-tective effect on hemostasis in rats.

. Background. Hypoxic-ischemic brain injury is one primary cause of long-term neurological disability, morbidity, and death worldwide. The decrease in blood flow and oxygen concentration leads to insufficient nutrient supply to the brain, energy depletion, increased free radical generation, and mitochondrial dysfunction. Perinatal asphyxia — the oxygen supply suspension near birth-time — causes hypoxic-ischemic brain injury and is a major risk factor for neurodevelopmental damage. In pathological scenarios, raloxifene, a selective estrogen receptor modulator, has shown neuroprotective effects. Purpose. To examine whether raloxifene showed neuroprotection in an oxygen-glucose deprivation/reoxygenation astrocyte cell model. Methods. T98G cells in culture were treated with a glucose-free DMEM medium and incubated at 37ºC in a hypoxia chamber with 1% O2 for 3, 6, 12, and 24 hours. Cultures were supplemented with raloxifene 1, 10, and 100 nM during both glucose and oxygen deprivation and reoxygenation periods. Results. Raloxifene 100 nM and 10 nM improved cell survival — 65.34% and 70.56% — respectively compared to the control cell groups. Mitochondrial membrane potential was preserved by 58.9% 10 nM raloxifene and 81.57% 100 nM raloxifene cotreatment. Raloxifene cotreatment reduced superoxide production by 72.72% and peroxide production by 57%. Mitochondrial mass was preserved by 47.4%, 75.5%, and 89% in T98G cells exposed to 6-hour oxygen-glucose deprivation followed by 3, 6, and 9 hours of reoxygenation, respectively. Conclusions. Raloxifene improved cell survival and mitochondrial membrane potential, and reduced lipid peroxidation and reactive oxygen species (ROS) production, suggesting a direct effect on mitochondria. Raloxifene protected the oxygen-glucose-deprived astrocyte cells used to mimic hypoxic-ischemic brain injury in this study.